STAT Therapeutics Awarded ACCEL-KS Grant to Accelerate D-CUFF™ Development

February 6, 2026

STAT Therapeutics Awarded ACCEL-KS Grant to Accelerate D-CUFF™ Development

Overland Park, Kan. - STAT Therapeutics is proud to announce that it has been selected as a recipient of proof-of-concept funding through the ACCEL-KS program administered by KU Innovation Park and supported by the Kansas Department of Commerce. STAT Therapeutics is among 16 innovative Kansas-based companies selected to receive grant awards to help advance early-stage technologies toward commercialization.

This award provides STAT Therapeutics with a proof-of-concept grant of $25,000, along with access to commercialization support, technical assistance and entrepreneurial education designed to accelerate innovation and reduce barriers to market entry.

“We are honored to be recognized by the ACCEL-KS program,” said Thomas Krol, founder and CEO of STAT Therapeutics. “This funding enables us to take critical next steps in the development of D-CUFF™, a novel drug-device combination designed to bring immediate, user-friendly intramuscular (IM) drug delivery to patients, caregivers and professionals alike.”

D-CUFF™ is a first-in-class drug-device combination product engineered to simplify the administration of injectable IM medicines by allowing for easy, consistent intramuscular delivery in non-clinical settings.

The ACCEL-KS proof-of-concept funding will be used to:
• Advance prototype development and testing of D-CUFF™ to demonstrate feasibility and performance.
• Conduct targeted market research in selected markets.

STAT Therapeutics extends its deep gratitude to the Kansas innovation community, Kansas Commerce and the KU Innovation Park team for their commitment to fostering early-stage technology development and helping Kansas entrepreneurs bring impactful solutions to market.

About STAT Therapeutics
STAT Therapeutics is a Kansas-based life sciences company focused on bringing accessible, high-impact medical technologies to patients and caregivers. The company’s lead innovation, D-CUFF™, is designed to enable immediate and reliable IM drug delivery outside of traditional healthcare settings, expanding access to critical treatments. For more information, visit www.stattherapeutics.com.

#DrugDelivery #IMinjection #ClinicalResearch #Pharmaceuticals #Biotechnology #STATTherapeutics #Innovation #Autoinjector #MedicalDevices #ClinicalScience